OJEMDA™ (tovorafenib) launch underway following U.S. FDA accelerated approval for relapsed or refractory BRAF-altered Pediatric Low-Grade Glioma (pLGG) .
Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN – Get Free Report) CFO Charles N. York II sold 52,183 shares of the stock in a transaction dated Wednesday, May 1st. The stock was sold at an average price of $17.89, for a total transaction of $933,553.87. Following the transaction, the chief financial officer now directly owns 225,571 shares […]
Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN – Get Free Report) CEO Jeremy Bender sold 70,051 shares of the firm’s stock in a transaction dated Wednesday, May 1st. The shares were sold at an average price of $17.88, for a total transaction of $1,252,511.88. Following the transaction, the chief executive officer now owns 651,762 shares of the […]
Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN – Get Free Report)’s share price was up 5.2% during mid-day trading on Monday . The company traded as high as $16.03 and last traded at $15.70. Approximately 267,345 shares traded hands during trading, a decline of 68% from the average daily volume of 837,835 shares. The stock had previously […]
Wedbush reissued their outperform rating on shares of Day One Biopharmaceuticals (NASDAQ:DAWN – Free Report) in a research report report published on Wednesday morning, RTT News reports. The brokerage currently has a $33.00 target price on the stock. Wedbush also issued estimates for Day One Biopharmaceuticals’ Q3 2025 earnings at ($0.32) EPS and FY2025 earnings […]